2'-F-ara-deoxyuridine

also known as FAU

Developed for: adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · Burkitt lymphoma · cancer of unknown primary site · chronic lymphocytic leukemia/small lymphocytic lymphoma · extranodal nasal NK/T cell lymphoma · grade III lymphomatoid granulomatosis
+10 more
· Hodgkins lymphoma · large-cell immunoblastic lymphoma · MALT lymphoma · mantle cell lymphoma · mycosis fungoides and variants · nodal marginal zone B-cell lymphoma · primary cutaneous B-cell lymphoma · small intestine lymphoma · splenic marginal zone lymphoma · Waldenstrom macroglobulinemia
Investigated by: National Cancer Institute (NCI)

today NCT00769288 · Ph 1

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00769288	Jul 2009 → Dec 2013	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +14	National Cancer Institute (NCI)	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	2'-F-ara-deoxyuridine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00769288 ↗
Known as	FAU	“A Phase I Study of Intravenously Administered FAU (1-(2'-Deoxy-2'-Fluoro-B-D-arabinofuranosyl) Uracil, NSC#678515) in Patients With Advanced Solid Tumors” NCT00769288 ↗
Route	Intravenous	“Given IV” NCT00769288 ↗